'Gleason score' presentation slideshows

MANAGEMENT OF EARLY PROSTATE CANCER

MANAGEMENT OF EARLY PROSTATE CANCER. INTRODUCTION. Prostate cancer represents 4.9% of all cancer incidences , and its average incidence all over the world is about 3.4 /100000 population. It ranks 9 th among all cancers all over the world.

757 views • 61 slides

MANAGEMENT OF EARLY PROSTATE CANCER

MANAGEMENT OF EARLY PROSTATE CANCER. BY: EHAB ESMAT FAWZY M.D. ONCOLOGY FACULTY OF MEDICINE CAIRO UNIVRSITY. INTRODUCTION. Prostate cancer represents 4.9% of all cancer incidences , and its average incidence all over the world is about 3.4 /100000 population.

772 views • 61 slides

MANAGEMENT OF EARLY PROSTATE CANCER

MANAGEMENT OF EARLY PROSTATE CANCER. BY: EHAB ESMAT FAWZY M.D. ONCOLOGY FACULTY OF MEDICINE CAIRO UNIVRSITY. INTRODUCTION. Prostate cancer represents 4.9% of all cancer incidences , and its average incidence all over the world is about 3.4 /100000 population.

780 views • 61 slides

Everything you need to know about Prostate Radiotherapy During the talk or at end send

Everything you need to know about Prostate Radiotherapy During the talk or at end send QUESTIONS: 1 855-223-5455 QUESTIONS@PROSTATECANCERNETWORK.CA Rob Rutledge, MD, Radiation Oncologist Associate Professor, Dalhousie University CEO, the Healing and Cancer Foundation. OVERVIEW OF TALK.

666 views • 55 slides

NDA 20-498 / S012 CASODEX (bicalutamide) 150 mg

NDA 20-498 / S012 CASODEX (bicalutamide) 150 mg. FDA Review Division of Reproductive and Urologic Drug Products (DRUDP). Outline of FDA Presentation. Background and Review Issues Dan Shames, M.D., Director, DRUDP Review of Clinical Trial Data Scott Monroe, M.D., Medical Team Leader, DRUDP

638 views • 51 slides

PROSTATE CANCER

Is there a role for adjuvant/neoadjuvant chemotherapy in High risk prostate cancer? Giuseppe Procopio Fondazione IRCCS Istituto Nazionale Tumori Milano. PROSTATE CANCER. USA prostate cancer incidence/mortality: 218.890 new cases /27.050 deaths in 2007

785 views • 39 slides

Steven Joniau Filip Ameye

Implementation of nomograms into clinical practice. Steven Joniau Filip Ameye. Clinical value of nomograms. Important role in the process of decision aid and patient counseling Predictive accuracy Statistical vs clinical significance

497 views • 37 slides

Surgical Treatment of Locally Advanced PCa

Surgical Treatment of Locally Advanced PCa. Bertrand Guillonneau, MD, PhD, dr hc Chief, service of urology, DCSS, Paris, France. Surgery and Locally Advanced PCa. Which definition for LAPCa ? How to diagnose before treatment? Rationale for surgery?

370 views • 36 slides

Post Op Positive Apex Margins Case 3: Prostate_3

Post Op Positive Apex Margins Case 3: Prostate_3. Case 3

475 views • 34 slides

Prostate cancer diagnosis today

Prostate cancer diagnosis today. Mungai Ngugi. Introduction. Prostate cancer remains a major problem in the world and particularly in black people who have the highest incidence in the world. ( Ngugi/magoha) Its incidence in the east African region has been rising

447 views • 32 slides

Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?

Is Radical Prostatectomy Adequate For High Risk Prostate Cancer?. Dr Manish Patel Urological Cancer Surgeon Westmead Hospital University of Sydney. What is High Risk. High Risk For Recurrence and Progression following Definitive Therapy. Localised High Risk Gleason score 8-10

520 views • 25 slides

Multigene Genomic Testing (ONCOTYPE DX) among New York Prostate Cancer Patients

Multigene Genomic Testing (ONCOTYPE DX) among New York Prostate Cancer Patients. Jovanka N Harrison , Amy R Kahn, Maria J Schymura New York State Cancer Registry. NAACCR/IARC Combined Annual Conference, Vancouver, Canada, June 11, 2019. Background.

229 views • 22 slides

Prostate Cancer: Treatment choices

Prostate Cancer: Treatment choices. Winston W Tan MD FACP Senior Consultant Genitourinary Oncology Mayo Clinic Florida. Incidence. 230,000 cases each year 30,000 deaths each year Indolent Aggressive disease Jemal et al 2009.

168 views • 15 slides

348 views • 9 slides

American Journal of Clinical Anatomy & Physiology

Introduction: Biochemical recurrence after radical prostatectomy has been associated with Gleason pattern 5(GP5) and Prostatic Specific Antigen (PSA) is a sensitive marker of relapse. Was analyzed the correlation between the Gleason score 7(group 2 e 3), pattern Gleason 5, biochemical recurrence and its correlation with other adverse histologicalfi ndings. Material and Methods: Historic cohort comprising 219 patients, subjected to score 7 radical prostatectomy with acinar adenocarcinoma and GP5 represents 5% or less of tumor size. Recurrence was determined as postoperative PSA less or equal 0.2/ ml in the second postprostatectomy assessment. Were considered as significant value of p < or equal to 0,005. All statistical analysis were conducted using the SPSS (SPSS Inc: released 2009, version 18.0, Chicago, IL, USA).

72 views • 4 slides

Non-specific HIF1? inhibitors in men receiving androgen deprivation therapy for prostate cancer

No. 086. Non-specific HIF1? inhibitors in men receiving androgen deprivation therapy for prostate cancer . Weranja Ranasinghe 1,2 , Shomik Sengupta 1 , Scott Williams 3 , Mike Chang 1 , Arthur Shulkes 1 , Damien Bolton 1 , Graham Baldwin 1 , Oneel Patel 1

185 views • 1 slides

Introduction

No. 098. A pilot study to assess the relationship between ADC values and Gleason scores in prostate cancer: Implications for a Gleason score predictor. Luke Waldron; Alain Lavoipierre ; Mark Frydenberg ; Dean Federman ; Andrew Ryan; David Di Domenico. Posters Proudly Supported by:.

165 views • 1 slides

Supplementary Figure 1

Supplementary Figure 1. A. B. C. *. Staining score. Gleason score. D. E. F. r s = -0.135 p = n.s. r s = 0.159 p = 0.0014. r s = -0.005 p = n.s.

63 views • 1 slides